219 related articles for article (PubMed ID: 35556229)
1. SS18-SSX drives CREB activation in synovial sarcoma.
Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
[TBL] [Abstract][Full Text] [Related]
2. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
4. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
[TBL] [Abstract][Full Text] [Related]
5. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
6. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
[TBL] [Abstract][Full Text] [Related]
7. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
8. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
[TBL] [Abstract][Full Text] [Related]
10. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
11. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
[TBL] [Abstract][Full Text] [Related]
12. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
[TBL] [Abstract][Full Text] [Related]
13. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
[TBL] [Abstract][Full Text] [Related]
14. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
15. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
16. First cloned human immortalized adipose derived mesenchymal stem-cell line with chimeric SS18-SSX1 gene (SS-iASC).
Mihály D; Matula Z; Changchien YC; Papp G; Tátrai P; Sápi Z
Cancer Genet; 2017 Oct; 216-217():52-60. PubMed ID: 29025595
[TBL] [Abstract][Full Text] [Related]
17. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.
Jones KB; Su L; Jin H; Lenz C; Randall RL; Underhill TM; Nielsen TO; Sharma S; Capecchi MR
Oncogene; 2013 May; 32(18):2365-71, 2375.e1-5. PubMed ID: 22797074
[TBL] [Abstract][Full Text] [Related]
18. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
[TBL] [Abstract][Full Text] [Related]
19. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
20. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
